Agilent Technologies Names Massachusetts Eye and Ear Infirmary as Certified
Service Provider for Next-Generation Sequencing and aCGH Solutions
SANTA CLARA, Calif. -- October 24, 2013
Agilent Technologies Inc. (NYSE:A) today announced that the Massachusetts Eye
and Ear Infirmary, an affiliate of Harvard Medical School, has been authorized
as a Certified Service Provider of Agilent’s next-generation target enrichment
and microarray-based comparative genomic hybridization (aCGH) solutions. MEEI
is home to the medical school’s Department of Ophthalmology Ocular Genomics
Institute, which is working to harness the power of genomics and gene therapy
to advance the knowledge and treatment of blinding eye diseases.
“Becoming an Agilent CSP enables us to provide the ocular genomics research
community with access to the latest protocols and technologies we are using at
Mass. Eye and Ear with ever-increasing success,” said Dr. Eric Pierce,
director of the Ocular Genomics Institute. “It is our hope that these tools
will help advance studies in genomic research and gene therapy. In addition,
incorporating the Agilent Bravo Automated Liquid Handling platform into our
service offerings will enable us to quickly process large volumes of samples
for even more researchers and for a wide range of genomics applications. We
are using these approaches to provide improved clinical genetic diagnostic
testing services for patients with inherited eye disorders.”
“We are excited to have MEEI as part of the Agilent CSP program,” said Victor
Fung, senior director of marketing for Agilent’s Genomics Solutions Division.
“MEEI has used Agilent’s NGS target enrichment and aCGH solutions for several
years in their retinal degeneration mutational disease research. We look
forward to supporting them as they expand their services outside of the
About the Agilent Certified Service Provider Program
Agilent offers its CSP program to select service provider laboratories
interested in using its market-leading technologies to provide the
highest-quality analysis services to their customers. The company offers two
certification paths: Agilent’s CGH microarray platform and its upstream target
enrichment next-generation sequencing platform. Hands-on training is also
provided by field application scientists to ensure customers receive
consistent data quality, reproducibility and reliability.
About Massachusetts Eye and Ear Infirmary
Founded in 1824, Massachusetts Eye and Ear Infirmary clinicians and scientists
are driven by a mission to find cures for blindness, deafness and diseases of
the head and neck. After uniting with Schepens Eye Research Institute, Mass.
Eye and Ear in Boston became the world’s largest vision and hearing research
center, offering hope and healing to patients everywhere through discovery and
innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital
and trains future medical leaders in ophthalmology and otolaryngology, through
residency as well as clinical and research fellowships. Internationally
acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time,
board-certified physicians who offer high-quality and affordable specialty
care that ranges from the routine to the very complex. U.S. News & World
Report’s “Best Hospitals Survey” has consistently ranked the Mass. Eye and Ear
Departments of Otolaryngology and Ophthalmology as among the top hospitals in
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at www.agilent.com/go/news.
Agilent Technologies Inc.
Susan Berg, +1-408-553-7093
Press spacebar to pause and continue. Press esc to stop.